研究室業績2007-2020

20202019201820172016201520142013201220112010200920082007

2016

脳腫瘍幹細胞研究によるグリオーマ治療戦略

福井伸行、サンペトラ・オルテア
【脳神経外科診療プラクティス 7】 グリオーマ治療のDecision Making 文光堂 2016

Development of mouse models of malignant phyllodes tumors by transplantation of syngeneic mammary gland cells expressing mutant H-Ras.

Takamoto Y, Arima Y, Saya H.
Genes Cells. 2016 Nov;21(11):1244-1252. doi: 10.1111/gtc.12435.

【脳腫瘍学-基礎研究と臨床研究の進歩-】脳腫瘍の分子生物学と発生機序 分子生物学 脳腫瘍におけるp53変異

前田 祐介, サンペトラ・オルテア , 佐谷 秀行
日本臨床 2016 Sep 74巻増刊7 脳腫瘍学 Page112-116

Sulfasalazine, a therapeutic agent for ulcerative colitis, inhibits the growth of CD44v9(+) cancer stem cells in ulcerative colitis-related cancer.

Seishima R, Okabayashi K, Nagano O, Hasegawa H, Tsuruta M, Shimoda M, Kameyama K, Saya H, Kitagawa Y.
Clin Res Hepatol Gastroenterol. 2016 Sep;40(4):487-93. doi: 10.1016/j.clinre.2015.11.007.

Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors.

Kanagawa H, Masuyama R, Morita M, Sato Y, Niki Y, Kobayashi T, Katsuyama E, Fujie A, Hao W, Tando T, Watanabe R, Miyamoto K, Morioka H, Matsumoto M, Toyama Y, Saya H, Miyamoto T.
J Bone Miner Metab. 2016 Sep;34(5):526-31. doi: 10.1007/s00774-015-0702-2.

p53 mutations in brain tumors.

Maeda Y, Sampetrean O, Saya H.
Nihon Rinsho. 2016 Sep;74 Suppl 7:112-116. Japanese.

転写因子による上皮間葉転換の制御とがん幹細胞

有馬好美、佐藤 亮
実験医学 2016 Sep 34巻5号 Page2283-2287

Salt-Inducible Kinase 2 Couples Ovarian Cancer Cell Metabolism with Survival at the Adipocyte-Rich Metastatic Niche.

Miranda F, Mannion D, Liu S, Zheng Y, Mangala LS, Redondo C, Herrero-Gonzalez S, Xu R, Taylor C, Chedom DF, Karaminejadranjbar M, Albukhari A, Jiang D, Pradeep S, Rodriguez-Aguayo C, Lopez-Berestein G, Salah E, Abdul Azeez KR, Elkins JM, Campo L, Myers KA, Klotz D, et al.
Cancer Cell. 2016 Aug 8;30(2):273-289. doi: 10.1016/j.ccell.2016.06.020.

Variant isoforms of CD44 expression in upper tract urothelial cancer as a predictive marker for recurrence and mortality.

Hagiwara M, Kikuchi E, Kosaka T, Mikami S, Saya H, Oya M.
Urol Oncol. 2016 Aug;34(8):337.e19-26. doi: 10.1016/j.urolonc.2016.03.015.

Histopathological investigation of glioblastomas resected under bevacizumab treatment.

Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetrean O, Kono M, Mizutani K, Yamamoto Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H.
Oncotarget. 2016 Aug 9;7(32):52423-52435. doi: 10.18632/oncotarget.9387.

ALK(R1275Q) perturbs extracellular matrix, enhances cell invasion and leads to the development of neuroblastoma in cooperation with MYCN.

Ueda T, Nakata Y, Yamasaki N, Oda H, Sentani K, Kanai A, Onishi N, Ikeda K, Sera Y, Honda ZI, Tanaka K, Sata M, Ogawa S, Yasui W, Saya H, Takita J, Honda H.
Oncogene. 2016 Aug 25;35(34):4447-58. doi: 10.1038/onc.2015.519.

Isolation of All CD44 Transcripts in Human Epidermis and Regulation of Their Expression by Various Agents.

Teye K, Numata S, Ishii N, Krol RP, Tsuchisaka A, Hamada T, Koga H, Karashima T, Ohata C, Tsuruta D, Saya H, Haftek M, Hashimoto T.
PLoS One. 2016 Aug 9;11(8):e0160952. doi: 10.1371/journal.pone.0160952.

Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets.

Sato R, Semba T, Saya H, Arima Y.
Stem Cells. 2016 Aug;34(8):1997-2007. doi: 10.1002/stem.2406.

CD44 variant-dependent redox status regulation in liver fluke-associated cholangiocarcinoma: A target for cholangiocarcinoma treatment.

Thanee M, Loilome W, Techasen A, Sugihara E, Okazaki S, Abe S, Ueda S, Masuko T, Namwat N, Khuntikeo N, Titapun A, Pairojkul C, Saya H, Yongvanit P.
Cancer Sci. 2016 Jul;107(7):991-1000. doi: 10.1111/cas.12967.

病態からみた子宮内膜症新規治療薬の開発 子宮内膜症患者におけるトラニラスト(リザベン)の疼痛改善効果

本田 律生, 岡村 佳則, 本田 智子, 伊藤 史子, 片渕 秀隆, 佐谷 秀行
日本エンドメトリオーシス学会会誌37巻 2016 Jul Page40-44

CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.

Sosulski A, Horn H, Zhang L, Coletti C, Vathipadiekal V, Castro CM, Birrer MJ, Nagano O, Saya H, Lage K, Donahoe PK, Pテゥpin D.
PLoS One. 2016 Jun 2;11(6):e0156595. doi: 10.1371/journal.pone.0156595.

LATS-YAP/TAZ controls lineage specification by regulating TGFβ signaling and Hnf4α expression during liver development.

Lee DH, Park JO, Kim TS, Kim SK, Kim TH, Kim MC, Park GS, Kim JH, Kuninaka S, Olson EN, Saya H, Kim SY, Lee H, Lim DS.
Nat Commun. 2016 Jun 30;7:11961. doi: 10.1038/ncomms11961.

Eradication of CD44-variant positive population in head and neck tumors through controlled intracellular navigation of cisplatin-loaded nanomedicines.

Wang M, Miura Y, Tsuchihashi K, Miyano K, Nagano O, Yoshikawa M, Tanabe A, Makino J, Mochida Y, Nishiyama N, Saya H, Cabral H, Kataoka K.
J Control Release. 2016 May 28;230:26-33. doi: 10.1016/j.jconrel.2016.03.038.

MIF Maintains the Tumorigenic Capacity of Brain Tumor-Initiating Cells by Directly Inhibiting p53.

Fukaya R, Ohta S, Yaguchi T, Matsuzaki Y, Sugihara E, Okano H, Saya H, Kawakami Y, Kawase T, Yoshida K, Toda M.
Cancer Res. 2016 May 1;76(9):2813-23. doi: 10.1158/0008-5472.CAN-15-1011.

Generation of heterozygous fibrillin-1 mutant cloned pigs from genome-edited foetal fibroblasts.

Umeyama K, Watanabe K, Watanabe M, Horiuchi K, Nakano K, Kitashiro M, Matsunari H, Kimura T, Arima Y, Sampetrean O, Nagaya M, Saito M, Saya H, Kosaki K, Nagashima H, Matsumoto M.
Sci Rep. 2016 Apr 14;6:24413. doi: 10.1038/srep24413.

GANP protein encoded on human chromosome 21/mouse chromosome 10 is associated with resistance to mammary tumor development.

Kuwahara K, Yamamoto-Ibusuki M, Zhang Z, Phimsen S, Gondo N, Yamashita H, Takeo T, Nakagata N, Yamashita D, Fukushima Y, Yamamoto Y, Iwata H, Saya H, Kondo E, Matsuo K, Takeya M, Iwase H, Sakaguchi N.
Cancer Sci. 2016 Apr;107(4):469-77. doi: 10.1111/cas.12883.

CD44 variant 9 is a potential biomarker of tumor initiating cells predicting survival outcome in hepatitis C virus-positive patients with resected hepatocellular carcinoma.

Kakehashi A, Ishii N, Sugihara E, Gi M, Saya H, Wanibuchi H.
Cancer Sci. 2016 May;107(5):609-18. doi: 10.1111/cas.12908.

Tumour resistance in induced pluripotent stem cells derived from naked mole-rats.

Miyawaki S, Kawamura Y, Oiwa Y, Shimizu A, Hachiya T, Bono H, Koya I, Okada Y, Kimura T, Tsuchiya Y, Suzuki S, Onishi N, Kuzumaki N, Matsuzaki Y, Narita M, Ikeda E, Okanoya K, Seino K, Saya H, Okano H, Miura K.
Nat Commun. 2016 May 10;7:11471. doi: 10.1038/ncomms11471.

The EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-).

Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetrean O, Onishi N, Wakimoto H, Yoshikawa M, Seishima R, Iwasaki Y, Morikawa T, Abe S, Takao A, Shimizu M, Masuko T, Nagane M, Furnari FB, Akiyama T, Suematsu M, Baba E, Akashi K, Saya H, et al.
Cancer Res. 2016 May 15;76(10):2954-63. doi: 10.1158/0008-5472.CAN-15-2121.

Potential of sulfasalazine as a therapeutic sensitizer for CD44 splice variant 9-positive urogenital cancer.

Takayama T, Kubo T, Morikawa A, Morita T, Nagano O, Saya H.
Med Oncol. 2016 May;33(5):45. doi: 10.1007/s12032-016-0760-x.

Myeloid Differentiation Factor 88 Signaling in Bone Marrow-Derived Cells Promotes Gastric Tumorigenesis by Generation of Inflammatory Microenvironment.

Maeda Y, Echizen K, Oshima H, Yu L, Sakulsak N, Hirose O, Yamada Y, Taniguchi T, Jenkins BJ, Saya H, Oshima M.
Cancer Prev Res (Phila). 2016 Mar;9(3):253-63. doi: 10.1158/1940-6207.CAPR-15-0315.

Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.

Hayakawa Y, Kawada M, Nishikawa H, Ochiya T, Saya H, Seimiya H, Yao R, Hayashi M, Kai C, Matsuda A, Naoe T, Ohtsu A, Okazaki T, Saji H, Sata M, Sugimura H, Sugiyama Y, Toi M, Irimura T.
Cancer Sci. 2016 Feb;107(2):189-202. doi: 10.1111/cas.12857.

Correction: Arsenic Trioxide Sensitizes Glioblastoma to a Myc Inhibitor.

Yoshimura Y, Shiino A, Muraki K, Fukami T, Yamada S, Satow T, Fukuda M, Saiki M, Hojo M, Miyamoto S, Onishi N, Saya H, Inubushi T, Nozaki K, Tanigaki K.
PLoS One. 2016 Feb 16;11(2):e0149826. doi: 10.1371/journal.pone.0149826.

【慢性炎症とがん】がん微小環境とがんの増殖・浸潤・転移 がん幹細胞における酸化ストレス抵抗性機構

佐谷 秀行
別冊Bio Clinica: 慢性炎症と疾患5巻1号 2016 Feb Page60-64

Therapeutic strategies targeting cancer stem cells.

Yoshida GJ, Saya H.
Cancer Sci. 2016 Jan;107(1):5-11. doi: 10.1111/cas.12817.

Development of an ErbB4 monoclonal antibody that blocks neuregulin-1-induced ErbB4 activation in cancer cells.

Okazaki S, Nakatani F, Masuko K, Tsuchihashi K, Ueda S, Masuko T, Saya H, Nagano O.
Biochem Biophys Res Commun. 2016 Jan 29;470(1):239-244. doi: 10.1016/j.bbrc.2016.01.045.